24 July 2020 : Database Analysis
Prognostic Value of Enolase Gene Family in Colon Cancer
Xiaohang Pan1AC, Huawen Wu1BF, Guofu Chen1EF, Wenhuan Li1AD*DOI: 10.12659/MSM.922980
Med Sci Monit 2020; 26:e922980
Table 2 Prognostic survival analysis of ENO family genes.
Gene expression | Patients (n=438) | No. of events (%) | MST (days) | Crude HR (95% CI) | Crude P | Adjusted HR (95% CI) | Adjusted P* |
---|---|---|---|---|---|---|---|
0.243 | 0.840 | ||||||
Low | 219 | 76.7 | 2309 | Ref. | Ref. | ||
High | 219 | 78.5 | 2933 | 0.788 (0.528–1.175) | 1.044 (0.689–1.580) | ||
0.003 | 0.020 | ||||||
Low | 219 | 83.1 | 3016 | Ref. | Ref. | ||
High | 219 | 72.1 | 2311 | 0.543 (0.361–0.817) | 0.604 (0.395–0.923) | ||
<0.001 | <0.001 | ||||||
Low | 219 | 85.8 | 3033 | Ref. | Ref. | ||
High | 219 | 69.4 | 2365 | 0.439 (0.287–0.673) | 0.452 (0.292–0.699) | ||
0.801 | 0.685 | ||||||
Low | 219 | 79.0 | 2784 | Ref. | Ref. | ||
High | 219 | 76.3 | 2566 | 1.052 (0.707–1.566) | 0.919 (0.611–1.382) | ||
* Adjusted for TNM stage. – enolase; MST – median survival time; HR – hazard ratio; CI – confidence interval. |